Strides Pharma Science informs about press release

04 Nov 2019 Evaluate

Strides Pharma Science has informed about Press Release issued by the Company titled: USFDA announces Laboratory testing and analysis of Ranitidine and issues statement with acceptable NDMA limits. Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits. 

The above information is a part of company’s filings submitted to BSE.

Strides Pharma Scien Share Price

869.40 -31.25 (-3.47%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×